-
Product Insights
New![]()
Yellow Medicine County Pump Storage Project
Yellow Medicine County Pump Storage Project is a Hydro project located in Minnesota, United States. The project is owned and being developed by Midwest Energy Recycling LLC. The project is expected to come online in 2033. Empower your strategies with our Yellow Medicine County Pump Storage Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
New![]()
Net Present Value Model: Revolution Medicines Inc’s RMC-6236
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Revolution Medicines Inc’s RMC-6291
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Mind Medicine MindMed Inc’s Zolunicant Hydrochloride
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Praxis Precision Medicines Inc’s PRAX-944
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Mind Medicine MindMed Inc’s MM-120
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Mind Medicine MindMed Inc’s MM-290
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
Clinical Trials – Precision and Personalized Medicine
This report provides analysis of clinical research involving precision and personalized medicines and identifies trends throughout the years. The terms precision and personalized medicine are often used interchangeably as they refer to similar types of treatment. They both define the stratification of patients within a disease segment using their genomic and phenotypic variations to find targeted therapies. This is an alternative to the traditional process of drug design, which typically follows a one-size-fits all approach. Precision and personalized medicine is...
-
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GNR-079 in Cartilage Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GNR-079 in Cartilage Degeneration Drug Details: GNR-079 is under development for the treatment of cartilage...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lixisenatide in Parkinson’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lixisenatide in Parkinson's Disease Drug Details: Lixisenatide (Lyxumia, Adlyxin) is an anti diabetic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Safinamide Mesylate in Drug-Induced Dyskinesia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Safinamide Mesylate in Drug-Induced Dyskinesia Drug Details: Safinamide mesylate (Xadago,Equfina ) is an alpha-aminoamide derivative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Safinamide Mesylate in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Safinamide Mesylate in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexin-G in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexin-G in Breast Cancer Drug Details: Rexin-G is under development for the treatment of chondrosarcoma,...
-
Product Insights
New![]()
Viridis Eolia Master Plan Wind Project
Viridis Eolia Master Plan Wind Project is an onshore wind project located in Wyoming, United States. The project is owned by Viridis Eolia LLC and is developed by Little Medicine Bow Wind S LLC; Viridis Eolia LLC. The project is at the permitting stage. Empower your strategies with our Viridis Eolia Master Plan Wind Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NVH-020B in Hemorrhage
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NVH-020B in Hemorrhage Drug Details: NVH-020B is under development for the treatment of hemorrhages and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HRS-8427 in Urinary Tract Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HRS-8427 in Urinary Tract Infections Drug Details: HRS-8427 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NIM-1324 in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NIM-1324 in Rheumatoid ArthritisDrug Details:NIM-1324 is under development for the treatment of rheumatoid arthritis and systemic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Thyroid in Hypothyroidism
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Thyroid in HypothyroidismDrug Details:Armour thyroid is under development for the treatment of hypothyroidism. The therapeutic candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lutetium 177Lu Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium 177Lu Oxodotreotide in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: Lutetium (177Lu) oxodotreotide is under...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.